Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Apotex Paxil Generics Earliest Launch Date Could Be September 2003

Executive Summary

Apotex' earliest potential launch date for its generic version of GSK's Paxil is September 2003

You may also be interested in...



Apotex Paxil ANDA: Presence Of Hemihydrate Does Not Infringe GSK’s Patent

Apotex' generic version of Paxil would not infringe GSK's hemihydrate paroxetine patent because the generic does not contain a commercially significant amount of hemihydrate crystals, a Chicago district court decision says

Apotex Paxil ANDA: Presence Of Hemihydrate Does Not Infringe GSK’s Patent

Apotex' generic version of Paxil would not infringe GSK's hemihydrate paroxetine patent because the generic does not contain a commercially significant amount of hemihydrate crystals, a Chicago district court decision says

GSK Switch Success: Paxil CR Has 31% Of New Scripts; Augmentin ES, 49%

GlaxoSmithKline has converted 31% of Paxil new prescriptions to the controlled-release version

Related Content

UsernamePublicRestriction

Register

OM013658

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel